ETF Holdings Breakdown of RCUS

Stock Name	Arcus Biosciences Inc
Ticker	RCUS(USD) NYSE
TYPE	Common Stock
Country	USA
ISIN	US03969F1093

RCUS institutional holdings

The following institutional investment holdings of RCUS have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 11,089 USD 182,636

2025-10-17 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 90,988 USD 1,498,572

2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 33,031 USD 544,021 -2.6%

Total = 135,108 USD 2,225,229
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	11,089	USD 182,636
2025-10-17	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	90,988	USD 1,498,572
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	33,031	USD 544,021 -2.6%
Total =	135,108	USD 2,225,229

News associated with RCUS

Arcus Biosciences, Inc. (NYSE:RCUS) Receives $21.14 Average Target Price from Analysts: Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target […] - 2025-09-09 02:29:02
US Bancorp DE Buys 12,869 Shares of Arcus Biosciences, Inc. (NYSE:RCUS): US Bancorp DE increased its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 186.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,756 shares of the company’s stock after acquiring an additional 12,869 shares during the period. US […] - 2025-08-17 05:14:59
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $21.14 Consensus Price Target from Brokerages: Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price […] - 2025-08-15 02:10:59
Universal Beteiligungs und Servicegesellschaft mbH Makes New $138,000 Investment in Arcus Biosciences, Inc. (NYSE:RCUS): Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 17,631 shares of the company’s stock, valued at approximately $138,000. A number of other […] - 2025-08-06 04:28:49
Y Intercept Hong Kong Ltd Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS): Y Intercept Hong Kong Ltd acquired a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 31,414 shares of the company’s stock, valued at approximately $247,000. A number of […] - 2025-07-31 05:00:52
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Louisiana State Employees Retirement System: Louisiana State Employees Retirement System boosted its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 31,700 shares of the company’s stock after purchasing an additional 5,600 shares during the quarter. Louisiana State […] - 2025-07-22 07:17:17
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Brokerages: Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong […] - 2025-06-23 03:12:48
GAMMA Investing LLC Purchases 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS): GAMMA Investing LLC lifted its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 1,399.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 16,571 shares of the company’s stock after purchasing an additional 15,466 shares during the period. GAMMA Investing LLC’s holdings in Arcus Biosciences were […] - 2025-06-16 04:26:49
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.3% in the fourth quarter, HoldingsChannel reports. The firm owned 62,014 shares of the company’s stock after selling 7,872 shares during the quarter. UBS AM a distinct business unit […] - 2025-06-11 04:36:52
ProShare Advisors LLC Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS): ProShare Advisors LLC lifted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 44.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 16,379 shares of the company’s stock after buying an additional 5,038 shares during the quarter. ProShare Advisors LLC’s holdings in Arcus Biosciences were worth $244,000 as of […] - 2025-06-01 05:46:50
Jane Street Group LLC Trims Stake in Arcus Biosciences, Inc. (NYSE:RCUS): Jane Street Group LLC cut its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 6.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 202,500 shares of the company’s stock after selling 14,541 shares during the quarter. Jane Street Group LLC’s holdings in Arcus Biosciences were worth $3,015,000 at the […] - 2025-05-14 06:38:56
Voya Investment Management LLC Acquires 6,733 Shares of Arcus Biosciences, Inc. (NYSE:RCUS): Voya Investment Management LLC increased its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 37.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 24,674 shares of the company’s stock after acquiring an additional 6,733 shares during the period. Voya Investment Management LLC’s holdings in Arcus Biosciences were worth $367,000 at […] - 2025-05-11 05:44:50
Arcus Biosciences (NYSE:RCUS) Shares Gap Down Following Weak Earnings: Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s stock price gapped down prior to trading on Wednesday following a weaker than expected earnings announcement. The stock had previously closed at $8.12, but opened at $7.44. Arcus Biosciences shares last traded at $7.47, with a volume of 384,839 shares trading hands. The company reported ($1.14) earnings […] - 2025-05-09 02:40:50
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LP: Dimensional Fund Advisors LP raised its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,702,302 shares of the company’s stock after buying an additional 178,351 shares during the period. Dimensional Fund Advisors LP’s holdings in Arcus Biosciences were worth […] - 2025-05-07 05:26:54
MetLife Investment Management LLC Purchases 2,521 Shares of Arcus Biosciences, Inc. (NYSE:RCUS): MetLife Investment Management LLC boosted its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 8.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,525 shares of the company’s stock after purchasing an additional 2,521 shares during the period. MetLife […] - 2025-05-06 05:41:07
Invesco Ltd. Raises Holdings in Arcus Biosciences, Inc. (NYSE:RCUS): Invesco Ltd. boosted its stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 203,987 shares of the company’s stock after buying an additional 35,905 shares during the quarter. Invesco Ltd.’s holdings in Arcus […] - 2025-04-28 04:54:53
Legal & General Group Plc Sells 1,837 Shares of Arcus Biosciences, Inc. (NYSE:RCUS): Legal & General Group Plc cut its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 1.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 149,207 shares of the company’s stock after selling 1,837 shares during the quarter. Legal & General Group Plc’s holdings in Arcus Biosciences were worth […] - 2025-04-25 05:10:47
KLP Kapitalforvaltning AS Makes New $207,000 Investment in Arcus Biosciences, Inc. (NYSE:RCUS): KLP Kapitalforvaltning AS purchased a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 13,900 shares of the company’s stock, valued at approximately $207,000. Other institutional investors and hedge funds have also […] - 2025-04-08 05:44:58
Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $30.25: Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) has been assigned a consensus rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-03-20 04:52:43
AlphaQuest LLC Has $110,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS): AlphaQuest LLC reduced its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 21.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,405 shares of the company’s stock after selling 2,026 shares during the quarter. AlphaQuest LLC’s holdings […] - 2025-03-19 06:10:45
Principal Financial Group Inc. Purchases 7,906 Shares of Arcus Biosciences, Inc. (NYSE:RCUS): Principal Financial Group Inc. increased its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 3.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 263,517 shares of the company’s stock after buying an additional 7,906 shares during the quarter. Principal Financial Group Inc.’s holdings in Arcus Biosciences were worth $3,924,000 at the […] - 2025-03-05 06:22:48
Handelsbanken Fonder AB Purchases 2,500 Shares of Arcus Biosciences, Inc. (NYSE:RCUS): Handelsbanken Fonder AB grew its position in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,800 shares of the company’s stock after purchasing an additional 2,500 shares during the quarter. Handelsbanken Fonder […] - 2025-03-03 06:59:09
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by New York State Teachers Retirement System: New York State Teachers Retirement System lowered its holdings in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 3.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 90,543 shares of the company’s stock after selling 3,708 shares during the quarter. New York State Teachers Retirement System’s holdings in Arcus Biosciences were worth $1,348,000 […] - 2025-02-24 06:25:09
Arcus Biosciences, Inc. (NYSE:RCUS) Receives $31.29 Average Target Price from Brokerages: Shares of Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong […] - 2025-02-21 04:48:43
Arcus Biosciences (NYSE:RCUS) Hits New 52-Week Low on Analyst Downgrade: Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s stock price hit a new 52-week low during trading on Wednesday after Morgan Stanley lowered their price target on the stock from $36.00 to $25.00. Morgan Stanley currently has an overweight rating on the stock. Arcus Biosciences traded as low as $10.65 and last traded at $11.00, […] - 2025-02-19 04:30:55
R Squared Ltd Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS): R Squared Ltd bought a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) in the 4th quarter, HoldingsChannel.com reports. The firm bought 1,720 shares of the company’s stock, valued at approximately $26,000. Other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Hong Kong […] - 2025-02-05 06:42:51

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.